Physician profile
Nathan Hand
NPI 1659314961
$2,007.67
in general payments reported to CMS, 2019-2025
16 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $380 · 2023: $754 · 2024: $406 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $383.75 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $328.80 | 2023-2024 | Vtama |
| Abbvie INC. | $316.65 | 2021-2023 | |
| Pfizer INC. | $264.00 | 2022-2025 | |
| Janssen Biotech, INC. | $166.82 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $82.73 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $82.66 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $79.43 | 2021-2023 | Absorica Ld, Winlevi |
| Organon LLC | $72.14 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $62.27 | 2021-2022 | |
| Celgene Corporation | $43.54 | 2024 | Sprycel, Sotyktu |
| Leo Pharma INC. | $37.87 | 2023 | Adbry |
| Amgen INC. | $30.48 | 2022 | |
| Vyne Pharmaceuticals INC. | $27.49 | 2021 | |
| Genzyme Corporation | $15.14 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.90 | 2023 | Taltz, Olumiant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.